SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '7AE'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1IEP_A_STIA201_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	7 / 12	LEU A 593 VAL A 601 ALA A 617 MET A 641 PHE A 673 GLY A 677 ALA A 740	7AE A1000 ( 3.9A) 7AE A1000 ( 4.9A) 7AE A1000 (-3.3A) None 7AE A1000 (-4.1A) 7AE A1000 ( 3.7A) 7AE A1000 ( 3.7A)	0.85A	1iepA-5td2A: 29.0	1iepA-5td2A: 41.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1IEP_B_STIB202_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	6 / 12	LEU A 593 ALA A 617 MET A 641 PHE A 673 ALA A 740 ASP A 741	7AE A1000 ( 3.9A) 7AE A1000 (-3.3A) None 7AE A1000 (-4.1A) 7AE A1000 ( 3.7A) 7AE A1000 (-4.4A)	1.05A	1iepB-5td2A: 28.9	1iepB-5td2A: 41.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1IEP_B_STIB202_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	7 / 12	LEU A 593 VAL A 601 ALA A 617 MET A 641 PHE A 673 GLY A 677 ALA A 740	7AE A1000 ( 3.9A) 7AE A1000 ( 4.9A) 7AE A1000 (-3.3A) None 7AE A1000 (-4.1A) 7AE A1000 ( 3.7A) 7AE A1000 ( 3.7A)	0.87A	1iepB-5td2A: 28.9	1iepB-5td2A: 41.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HYY_A_STIA600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	6 / 12	VAL A 601 ALA A 617 MET A 641 PHE A 673 GLY A 677 ALA A 740	7AE A1000 ( 4.9A) 7AE A1000 (-3.3A) None 7AE A1000 (-4.1A) 7AE A1000 ( 3.7A) 7AE A1000 ( 3.7A)	0.78A	2hyyA-5td2A: 28.9	2hyyA-5td2A: 43.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HYY_B_STIB600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	6 / 12	VAL A 601 ALA A 617 MET A 641 PHE A 673 GLY A 677 ALA A 740	7AE A1000 ( 4.9A) 7AE A1000 (-3.3A) None 7AE A1000 (-4.1A) 7AE A1000 ( 3.7A) 7AE A1000 ( 3.7A)	0.75A	2hyyB-5td2A: 29.2	2hyyB-5td2A: 43.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ITY_A_IREA2020_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	8 / 12	LEU A 593 GLY A 594 VAL A 601 ALA A 617 LYS A 619 MET A 641 GLY A 677 ASP A 741	7AE A1000 ( 3.9A) 7AE A1000 ( 4.2A) 7AE A1000 ( 4.9A) 7AE A1000 (-3.3A) 7AE A1000 (-3.1A) None 7AE A1000 ( 3.7A) 7AE A1000 (-4.4A)	0.83A	2ityA-5td2A: 24.2	2ityA-5td2A: 34.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2WGJ_A_VGHA2346_1 (HEPATOCYTE GROWTH FACTOR RECEPTOR)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	9 / 12	GLY A 594 VAL A 601 ALA A 617 LEU A 671 MET A 674 GLY A 677 MET A 730 ALA A 740 ASP A 741	7AE A1000 ( 4.2A) 7AE A1000 ( 4.9A) 7AE A1000 (-3.3A) 7AE A1000 (-3.7A) None 7AE A1000 ( 3.7A) 7AE A1000 (-3.6A) 7AE A1000 ( 3.7A) 7AE A1000 (-4.4A)	0.49A	2wgjA-5td2A: 30.9	2wgjA-5td2A: 43.49
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2XP2_A_VGHA9000_1 (TYROSINE-PROTEIN KINASE RECEPTOR)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	7 / 9	LEU A 593 VAL A 601 ALA A 617 LEU A 671 MET A 674 GLY A 677 ASP A 741	7AE A1000 ( 3.9A) 7AE A1000 ( 4.9A) 7AE A1000 (-3.3A) 7AE A1000 (-3.7A) None 7AE A1000 ( 3.7A) 7AE A1000 (-4.4A)	0.41A	2xp2A-5td2A: 29.4	2xp2A-5td2A: 37.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3AOX_A_EMHA901_1 (ALK TYROSINE KINASE RECEPTOR)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	6 / 10	LEU A 593 ALA A 617 LYS A 619 LEU A 671 MET A 674 GLY A 677	7AE A1000 ( 3.9A) 7AE A1000 (-3.3A) 7AE A1000 (-3.1A) 7AE A1000 (-3.7A) None 7AE A1000 ( 3.7A)	0.47A	3aoxA-5td2A: 11.8	3aoxA-5td2A: 35.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_A_NILA600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	6 / 12	ALA A 617 MET A 641 GLY A 677 PHE A 719 HIS A 721 ALA A 740	7AE A1000 (-3.3A) None 7AE A1000 ( 3.7A) None None 7AE A1000 ( 3.7A)	0.75A	3cs9A-5td2A: 29.5	3cs9A-5td2A: 42.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_B_NILB600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	5 / 12	ALA A 617 MET A 641 GLY A 677 HIS A 721 ALA A 740	7AE A1000 (-3.3A) None 7AE A1000 ( 3.7A) None 7AE A1000 ( 3.7A)	0.60A	3cs9B-5td2A: 30.3	3cs9B-5td2A: 42.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_C_NILC600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	6 / 12	ALA A 617 MET A 641 PHE A 673 PHE A 719 HIS A 721 ALA A 740	7AE A1000 (-3.3A) None 7AE A1000 (-4.1A) None None 7AE A1000 ( 3.7A)	0.80A	3cs9C-5td2A: 29.5	3cs9C-5td2A: 42.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_D_NILD600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	6 / 12	ALA A 617 MET A 641 GLY A 677 PHE A 719 HIS A 721 ALA A 740	7AE A1000 (-3.3A) None 7AE A1000 ( 3.7A) None None 7AE A1000 ( 3.7A)	0.66A	3cs9D-5td2A: 22.2	3cs9D-5td2A: 42.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_D_NILD600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	6 / 12	ALA A 617 MET A 641 PHE A 673 GLY A 677 HIS A 721 ALA A 740	7AE A1000 (-3.3A) None 7AE A1000 (-4.1A) 7AE A1000 ( 3.7A) None 7AE A1000 ( 3.7A)	0.61A	3cs9D-5td2A: 22.2	3cs9D-5td2A: 42.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MIY_B_B49B2_1 (TYROSINE-PROTEIN KINASE ITK/TSK)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	5 / 9	ALA A 617 LYS A 619 PHE A 673 MET A 674 GLY A 677	7AE A1000 (-3.3A) 7AE A1000 (-3.1A) 7AE A1000 (-4.1A) None 7AE A1000 ( 3.7A)	0.55A	3miyB-5td2A: 31.2	3miyB-5td2A: 38.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MS9_A_STIA1_1 (TYROSINE-PROTEIN KINASE ABL1)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	7 / 12	LEU A 593 VAL A 601 ALA A 617 MET A 641 PHE A 673 ALA A 740 ASP A 741	7AE A1000 ( 3.9A) 7AE A1000 ( 4.9A) 7AE A1000 (-3.3A) None 7AE A1000 (-4.1A) 7AE A1000 ( 3.7A) 7AE A1000 (-4.4A)	0.98A	3ms9A-5td2A: 29.1	3ms9A-5td2A: 41.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_A_STIA1_1 (TYROSINE-PROTEIN KINASE ABL1)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	6 / 12	LEU A 593 ALA A 617 MET A 641 PHE A 673 ALA A 740 ASP A 741	7AE A1000 ( 3.9A) 7AE A1000 (-3.3A) None 7AE A1000 (-4.1A) 7AE A1000 ( 3.7A) 7AE A1000 (-4.4A)	0.99A	3mssA-5td2A: 29.3	3mssA-5td2A: 41.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_A_STIA1_1 (TYROSINE-PROTEIN KINASE ABL1)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	6 / 12	LEU A 593 VAL A 601 ALA A 617 MET A 641 PHE A 673 ALA A 740	7AE A1000 ( 3.9A) 7AE A1000 ( 4.9A) 7AE A1000 (-3.3A) None 7AE A1000 (-4.1A) 7AE A1000 ( 3.7A)	0.75A	3mssA-5td2A: 29.3	3mssA-5td2A: 41.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_C_STIC1_1 (TYROSINE-PROTEIN KINASE ABL1)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	6 / 12	LEU A 593 ALA A 617 MET A 641 PHE A 673 ALA A 740 ASP A 741	7AE A1000 ( 3.9A) 7AE A1000 (-3.3A) None 7AE A1000 (-4.1A) 7AE A1000 ( 3.7A) 7AE A1000 (-4.4A)	1.00A	3mssC-5td2A: 29.4	3mssC-5td2A: 41.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_C_STIC1_1 (TYROSINE-PROTEIN KINASE ABL1)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	6 / 12	LEU A 593 VAL A 601 ALA A 617 MET A 641 PHE A 673 ALA A 740	7AE A1000 ( 3.9A) 7AE A1000 ( 4.9A) 7AE A1000 (-3.3A) None 7AE A1000 (-4.1A) 7AE A1000 ( 3.7A)	0.75A	3mssC-5td2A: 29.4	3mssC-5td2A: 41.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_D_STID1_1 (TYROSINE-PROTEIN KINASE ABL1)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	6 / 12	LEU A 593 ALA A 617 MET A 641 PHE A 673 ALA A 740 ASP A 741	7AE A1000 ( 3.9A) 7AE A1000 (-3.3A) None 7AE A1000 (-4.1A) 7AE A1000 ( 3.7A) 7AE A1000 (-4.4A)	1.00A	3mssD-5td2A: 29.3	3mssD-5td2A: 41.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_D_STID1_1 (TYROSINE-PROTEIN KINASE ABL1)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	6 / 12	LEU A 593 ALA A 617 MET A 641 PHE A 673 GLY A 677 ALA A 740	7AE A1000 ( 3.9A) 7AE A1000 (-3.3A) None 7AE A1000 (-4.1A) 7AE A1000 ( 3.7A) 7AE A1000 ( 3.7A)	0.84A	3mssD-5td2A: 29.3	3mssD-5td2A: 41.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3V5W_A_8PRA701_2 (G-PROTEIN COUPLED RECEPTOR KINASE 2)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	3 / 3	LEU A 671 MET A 674 ASP A 678	7AE A1000 (-3.7A) None 7AE A1000 ( 4.8A)	0.63A	3v5wA-5td2A: 10.0	3v5wA-5td2A: 17.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3WZE_A_BAXA1201_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	8 / 12	LEU A 593 VAL A 601 ALA A 617 LYS A 619 PHE A 673 GLY A 677 LEU A 714 HIS A 721	7AE A1000 ( 3.9A) 7AE A1000 ( 4.9A) 7AE A1000 (-3.3A) 7AE A1000 (-3.1A) 7AE A1000 (-4.1A) 7AE A1000 ( 3.7A) None None	0.67A	3wzeA-5td2A: 29.4	3wzeA-5td2A: 39.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ZBF_A_VGHA3000_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	8 / 12	LEU A 593 ALA A 617 LEU A 671 MET A 674 GLY A 677 ASP A 678 THR A 681 ASP A 741	7AE A1000 ( 3.9A) 7AE A1000 (-3.3A) 7AE A1000 (-3.7A) None 7AE A1000 ( 3.7A) 7AE A1000 ( 4.8A) None 7AE A1000 (-4.4A)	0.61A	3zbfA-5td2A: 30.4	3zbfA-5td2A: 40.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ANQ_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	8 / 9	LEU A 593 VAL A 601 ALA A 617 LEU A 671 MET A 674 GLY A 677 ALA A 740 ASP A 741	7AE A1000 ( 3.9A) 7AE A1000 ( 4.9A) 7AE A1000 (-3.3A) 7AE A1000 (-3.7A) None 7AE A1000 ( 3.7A) 7AE A1000 ( 3.7A) 7AE A1000 (-4.4A)	0.52A	4anqA-5td2A: 29.0	4anqA-5td2A: 34.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ANS_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	7 / 9	LEU A 593 VAL A 601 ALA A 617 MET A 674 GLY A 677 ALA A 740 ASP A 741	7AE A1000 ( 3.9A) 7AE A1000 ( 4.9A) 7AE A1000 (-3.3A) None 7AE A1000 ( 3.7A) 7AE A1000 ( 3.7A) 7AE A1000 (-4.4A)	0.57A	4ansA-5td2A: 28.9	4ansA-5td2A: 34.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ASD_A_BAXA1500_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	8 / 12	LEU A 593 VAL A 601 ALA A 617 LYS A 619 PHE A 673 GLY A 677 LEU A 714 HIS A 721	7AE A1000 ( 3.9A) 7AE A1000 ( 4.9A) 7AE A1000 (-3.3A) 7AE A1000 (-3.1A) 7AE A1000 (-4.1A) 7AE A1000 ( 3.7A) None None	0.72A	4asdA-5td2A: 29.0	4asdA-5td2A: 36.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4IAA_A_RTZA401_1 (SERINE/THREONINE-PRO TEIN KINASE PIM-1)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	6 / 11	VAL A 601 ALA A 617 LYS A 619 LEU A 671 ASP A 678 ASP A 741	7AE A1000 ( 4.9A) 7AE A1000 (-3.3A) 7AE A1000 (-3.1A) 7AE A1000 (-3.7A) 7AE A1000 ( 4.8A) 7AE A1000 (-4.4A)	0.75A	4iaaA-5td2A: 20.8	4iaaA-5td2A: 25.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4TWP_A_AXIA601_1 (TYROSINE-PROTEIN KINASE ABL1)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	8 / 12	VAL A 601 ALA A 617 PHE A 673 MET A 674 GLY A 677 ASN A 728 ALA A 740 ASP A 741	7AE A1000 ( 4.9A) 7AE A1000 (-3.3A) 7AE A1000 (-4.1A) None 7AE A1000 ( 3.7A) 7AE A1000 (-4.7A) 7AE A1000 ( 3.7A) 7AE A1000 (-4.4A)	0.60A	4twpA-5td2A: 29.9	4twpA-5td2A: 44.56
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4TWP_B_AXIB601_1 (TYROSINE-PROTEIN KINASE ABL1)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	9 / 12	LEU A 593 VAL A 601 ALA A 617 PHE A 673 MET A 674 GLY A 677 ASN A 728 ALA A 740 ASP A 741	7AE A1000 ( 3.9A) 7AE A1000 ( 4.9A) 7AE A1000 (-3.3A) 7AE A1000 (-4.1A) None 7AE A1000 ( 3.7A) 7AE A1000 (-4.7A) 7AE A1000 ( 3.7A) 7AE A1000 (-4.4A)	0.63A	4twpB-5td2A: 16.9	4twpB-5td2A: 44.56
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	8 / 11	LEU A 593 VAL A 601 ALA A 617 MET A 674 GLY A 677 ASN A 728 ALA A 740 ASP A 741	7AE A1000 ( 3.9A) 7AE A1000 ( 4.9A) 7AE A1000 (-3.3A) None 7AE A1000 ( 3.7A) 7AE A1000 (-4.7A) 7AE A1000 ( 3.7A) 7AE A1000 (-4.4A)	0.54A	4u5jA-5td2A: 21.7	4u5jA-5td2A: 38.13
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	6 / 9	LEU A 593 VAL A 601 ALA A 617 MET A 674 GLY A 677 ASP A 741	7AE A1000 ( 3.9A) 7AE A1000 ( 4.9A) 7AE A1000 (-3.3A) None 7AE A1000 ( 3.7A) 7AE A1000 (-4.4A)	0.71A	4u5jB-5td2A: 21.5	4u5jB-5td2A: 38.13
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4V01_A_0LIA1776_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	5 / 12	ALA A 617 MET A 641 LEU A 714 HIS A 721 ALA A 740	7AE A1000 (-3.3A) None None None 7AE A1000 ( 3.7A)	0.71A	4v01A-5td2A: 29.6	4v01A-5td2A: 41.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4V01_B_0LIB1770_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	5 / 12	ALA A 617 MET A 641 LEU A 714 HIS A 721 ALA A 740	7AE A1000 (-3.3A) None None None 7AE A1000 ( 3.7A)	0.59A	4v01B-5td2A: 29.9	4v01B-5td2A: 41.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4WA9_A_AXIA9000_1 (TYROSINE-PROTEIN KINASE ABL1)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	6 / 11	LEU A 593 ALA A 617 MET A 674 GLY A 677 ASN A 728 ALA A 740	7AE A1000 ( 3.9A) 7AE A1000 (-3.3A) None 7AE A1000 ( 3.7A) 7AE A1000 (-4.7A) 7AE A1000 ( 3.7A)	0.71A	4wa9A-5td2A: 27.8	4wa9A-5td2A: 42.38
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4WA9_B_AXIB9000_1 (TYROSINE-PROTEIN KINASE ABL1)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	7 / 12	VAL A 601 ALA A 617 PHE A 673 MET A 674 GLY A 677 ASN A 728 ALA A 740	7AE A1000 ( 4.9A) 7AE A1000 (-3.3A) 7AE A1000 (-4.1A) None 7AE A1000 ( 3.7A) 7AE A1000 (-4.7A) 7AE A1000 ( 3.7A)	0.61A	4wa9B-5td2A: 29.0	4wa9B-5td2A: 42.38
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5AAA_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	7 / 9	LEU A 593 VAL A 601 ALA A 617 LEU A 671 MET A 674 GLY A 677 ASP A 741	7AE A1000 ( 3.9A) 7AE A1000 ( 4.9A) 7AE A1000 (-3.3A) 7AE A1000 (-3.7A) None 7AE A1000 ( 3.7A) 7AE A1000 (-4.4A)	0.50A	5aaaA-5td2A: 12.8	5aaaA-5td2A: 38.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5AAB_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	7 / 10	LEU A 593 VAL A 601 ALA A 617 LEU A 671 MET A 674 GLY A 677 ASP A 741	7AE A1000 ( 3.9A) 7AE A1000 ( 4.9A) 7AE A1000 (-3.3A) 7AE A1000 (-3.7A) None 7AE A1000 ( 3.7A) 7AE A1000 (-4.4A)	0.51A	5aabA-5td2A: 21.1	5aabA-5td2A: 38.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5AAC_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	7 / 10	LEU A 593 VAL A 601 ALA A 617 LEU A 671 MET A 674 GLY A 677 ASP A 741	7AE A1000 ( 3.9A) 7AE A1000 ( 4.9A) 7AE A1000 (-3.3A) 7AE A1000 (-3.7A) None 7AE A1000 ( 3.7A) 7AE A1000 (-4.4A)	0.38A	5aacA-5td2A: 21.2	5aacA-5td2A: 37.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5AJQ_A_DB8A800_1 (SERINE/THREONINE-PRO TEIN KINASE 10)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	7 / 12	LEU A 593 GLY A 594 ALA A 617 PHE A 673 GLY A 677 ALA A 740 ASP A 741	7AE A1000 ( 3.9A) 7AE A1000 ( 4.2A) 7AE A1000 (-3.3A) 7AE A1000 (-4.1A) 7AE A1000 ( 3.7A) 7AE A1000 ( 3.7A) 7AE A1000 (-4.4A)	1.04A	5ajqA-5td2A: 17.8	5ajqA-5td2A: 25.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5XV7_A_EMHA705_1 (SERINE-ARGININE (SR) PROTEIN KINASE 1)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	5 / 12	LEU A 593 GLY A 594 VAL A 601 ALA A 617 ALA A 740	7AE A1000 ( 3.9A) 7AE A1000 ( 4.2A) 7AE A1000 ( 4.9A) 7AE A1000 (-3.3A) 7AE A1000 ( 3.7A)	0.28A	5xv7A-5td2A: 19.7	5xv7A-5td2A: 14.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6HD4_B_STIB602_1 (TYROSINE-PROTEIN KINASE ABL1)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	4 / 6	LEU A 593 PHE A 673 MET A 674 GLY A 677	7AE A1000 ( 3.9A) 7AE A1000 (-4.1A) None 7AE A1000 ( 3.7A)	0.60A	6hd4B-5td2A: 28.4	6hd4B-5td2A: 12.93

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1IEP_A_STIA201_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",7,"LEU A 593;VAL A 601;ALA A 617;MET A 641;PHE A 673;GLY A 677;ALA A 740","7AE A1000 ( 3.9A);7AE A1000 ( 4.9A);7AE A1000 (-3.3A);None;7AE A1000 (-4.1A);7AE A1000 ( 3.7A);7AE A1000 ( 3.7A)","0.85A","1iepA-5td2A:29.0",null],["1IEP_B_STIB202_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",6,"LEU A 593;ALA A 617;MET A 641;PHE A 673;ALA A 740;ASP A 741","7AE A1000 ( 3.9A);7AE A1000 (-3.3A);None;7AE A1000 (-4.1A);7AE A1000 ( 3.7A);7AE A1000 (-4.4A)","1.05A","1iepB-5td2A:28.9","1iepA-5td2A:41.69"],["1IEP_B_STIB202_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",7,"LEU A 593;VAL A 601;ALA A 617;MET A 641;PHE A 673;GLY A 677;ALA A 740","7AE A1000 ( 3.9A);7AE A1000 ( 4.9A);7AE A1000 (-3.3A);None;7AE A1000 (-4.1A);7AE A1000 ( 3.7A);7AE A1000 ( 3.7A)","0.87A","1iepB-5td2A:28.9","1iepB-5td2A:41.69"],["2HYY_A_STIA600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",6,"VAL A 601;ALA A 617;MET A 641;PHE A 673;GLY A 677;ALA A 740","7AE A1000 ( 4.9A);7AE A1000 (-3.3A);None;7AE A1000 (-4.1A);7AE A1000 ( 3.7A);7AE A1000 ( 3.7A)","0.78A","2hyyA-5td2A:28.9","1iepB-5td2A:41.69"],["2HYY_B_STIB600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",6,"VAL A 601;ALA A 617;MET A 641;PHE A 673;GLY A 677;ALA A 740","7AE A1000 ( 4.9A);7AE A1000 (-3.3A);None;7AE A1000 (-4.1A);7AE A1000 ( 3.7A);7AE A1000 ( 3.7A)","0.75A","2hyyB-5td2A:29.2","2hyyA-5td2A:43.25"],["2ITY_A_IREA2020_1","EPIDERMAL GROWTH FACTOR RECEPTOR","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",8,"LEU A 593;GLY A 594;VAL A 601;ALA A 617;LYS A 619;MET A 641;GLY A 677;ASP A 741","7AE A1000 ( 3.9A);7AE A1000 ( 4.2A);7AE A1000 ( 4.9A);7AE A1000 (-3.3A);7AE A1000 (-3.1A);None;7AE A1000 ( 3.7A);7AE A1000 (-4.4A)","0.83A","2ityA-5td2A:24.2","2hyyB-5td2A:43.25"],["2WGJ_A_VGHA2346_1","HEPATOCYTE GROWTH FACTOR RECEPTOR","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",9,"GLY A 594;VAL A 601;ALA A 617;LEU A 671;MET A 674;GLY A 677;MET A 730;ALA A 740;ASP A 741","7AE A1000 ( 4.2A);7AE A1000 ( 4.9A);7AE A1000 (-3.3A);7AE A1000 (-3.7A);None;7AE A1000 ( 3.7A);7AE A1000 (-3.6A);7AE A1000 ( 3.7A);7AE A1000 (-4.4A)","0.49A","2wgjA-5td2A:30.9","2ityA-5td2A:34.33"],["2XP2_A_VGHA9000_1","TYROSINE-PROTEIN KINASE RECEPTOR","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",7,"LEU A 593;VAL A 601;ALA A 617;LEU A 671;MET A 674;GLY A 677;ASP A 741","7AE A1000 ( 3.9A);7AE A1000 ( 4.9A);7AE A1000 (-3.3A);7AE A1000 (-3.7A);None;7AE A1000 ( 3.7A);7AE A1000 (-4.4A)","0.41A","2xp2A-5td2A:29.4","2wgjA-5td2A:43.49"],["3AOX_A_EMHA901_1","ALK TYROSINE KINASE RECEPTOR","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",6,"LEU A 593;ALA A 617;LYS A 619;LEU A 671;MET A 674;GLY A 677","7AE A1000 ( 3.9A);7AE A1000 (-3.3A);7AE A1000 (-3.1A);7AE A1000 (-3.7A);None;7AE A1000 ( 3.7A)","0.47A","3aoxA-5td2A:11.8","2xp2A-5td2A:37.74"],["3CS9_A_NILA600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",6,"ALA A 617;MET A 641;GLY A 677;PHE A 719;HIS A 721;ALA A 740","7AE A1000 (-3.3A);None;7AE A1000 ( 3.7A);None;None;7AE A1000 ( 3.7A)","0.75A","3cs9A-5td2A:29.5","3aoxA-5td2A:35.86"],["3CS9_B_NILB600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",5,"ALA A 617;MET A 641;GLY A 677;HIS A 721;ALA A 740","7AE A1000 (-3.3A);None;7AE A1000 ( 3.7A);None;7AE A1000 ( 3.7A)","0.60A","3cs9B-5td2A:30.3","3cs9A-5td2A:42.66"],["3CS9_C_NILC600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",6,"ALA A 617;MET A 641;PHE A 673;PHE A 719;HIS A 721;ALA A 740","7AE A1000 (-3.3A);None;7AE A1000 (-4.1A);None;None;7AE A1000 ( 3.7A)","0.80A","3cs9C-5td2A:29.5","3cs9B-5td2A:42.66"],["3CS9_D_NILD600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",6,"ALA A 617;MET A 641;GLY A 677;PHE A 719;HIS A 721;ALA A 740","7AE A1000 (-3.3A);None;7AE A1000 ( 3.7A);None;None;7AE A1000 ( 3.7A)","0.66A","3cs9D-5td2A:22.2","3cs9C-5td2A:42.66"],["3CS9_D_NILD600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",6,"ALA A 617;MET A 641;PHE A 673;GLY A 677;HIS A 721;ALA A 740","7AE A1000 (-3.3A);None;7AE A1000 (-4.1A);7AE A1000 ( 3.7A);None;7AE A1000 ( 3.7A)","0.61A","3cs9D-5td2A:22.2","3cs9D-5td2A:42.66"],["3MIY_B_B49B2_1","TYROSINE-PROTEIN KINASE ITK\/TSK","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",5,"ALA A 617;LYS A 619;PHE A 673;MET A 674;GLY A 677","7AE A1000 (-3.3A);7AE A1000 (-3.1A);7AE A1000 (-4.1A);None;7AE A1000 ( 3.7A)","0.55A","3miyB-5td2A:31.2","3cs9D-5td2A:42.66"],["3MS9_A_STIA1_1","TYROSINE-PROTEIN KINASE ABL1","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",7,"LEU A 593;VAL A 601;ALA A 617;MET A 641;PHE A 673;ALA A 740;ASP A 741","7AE A1000 ( 3.9A);7AE A1000 ( 4.9A);7AE A1000 (-3.3A);None;7AE A1000 (-4.1A);7AE A1000 ( 3.7A);7AE A1000 (-4.4A)","0.98A","3ms9A-5td2A:29.1","3miyB-5td2A:38.11"],["3MSS_A_STIA1_1","TYROSINE-PROTEIN KINASE ABL1","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",6,"LEU A 593;ALA A 617;MET A 641;PHE A 673;ALA A 740;ASP A 741","7AE A1000 ( 3.9A);7AE A1000 (-3.3A);None;7AE A1000 (-4.1A);7AE A1000 ( 3.7A);7AE A1000 (-4.4A)","0.99A","3mssA-5td2A:29.3","3ms9A-5td2A:41.69"],["3MSS_A_STIA1_1","TYROSINE-PROTEIN KINASE ABL1","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",6,"LEU A 593;VAL A 601;ALA A 617;MET A 641;PHE A 673;ALA A 740","7AE A1000 ( 3.9A);7AE A1000 ( 4.9A);7AE A1000 (-3.3A);None;7AE A1000 (-4.1A);7AE A1000 ( 3.7A)","0.75A","3mssA-5td2A:29.3","3mssA-5td2A:41.69"],["3MSS_C_STIC1_1","TYROSINE-PROTEIN KINASE ABL1","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",6,"LEU A 593;ALA A 617;MET A 641;PHE A 673;ALA A 740;ASP A 741","7AE A1000 ( 3.9A);7AE A1000 (-3.3A);None;7AE A1000 (-4.1A);7AE A1000 ( 3.7A);7AE A1000 (-4.4A)","1.00A","3mssC-5td2A:29.4","3mssA-5td2A:41.69"],["3MSS_C_STIC1_1","TYROSINE-PROTEIN KINASE ABL1","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",6,"LEU A 593;VAL A 601;ALA A 617;MET A 641;PHE A 673;ALA A 740","7AE A1000 ( 3.9A);7AE A1000 ( 4.9A);7AE A1000 (-3.3A);None;7AE A1000 (-4.1A);7AE A1000 ( 3.7A)","0.75A","3mssC-5td2A:29.4","3mssC-5td2A:41.69"],["3MSS_D_STID1_1","TYROSINE-PROTEIN KINASE ABL1","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",6,"LEU A 593;ALA A 617;MET A 641;PHE A 673;ALA A 740;ASP A 741","7AE A1000 ( 3.9A);7AE A1000 (-3.3A);None;7AE A1000 (-4.1A);7AE A1000 ( 3.7A);7AE A1000 (-4.4A)","1.00A","3mssD-5td2A:29.3","3mssC-5td2A:41.69"],["3MSS_D_STID1_1","TYROSINE-PROTEIN KINASE ABL1","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",6,"LEU A 593;ALA A 617;MET A 641;PHE A 673;GLY A 677;ALA A 740","7AE A1000 ( 3.9A);7AE A1000 (-3.3A);None;7AE A1000 (-4.1A);7AE A1000 ( 3.7A);7AE A1000 ( 3.7A)","0.84A","3mssD-5td2A:29.3","3mssD-5td2A:41.69"],["3V5W_A_8PRA701_2","G-PROTEIN COUPLED RECEPTOR KINASE 2","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",3,"LEU A 671;MET A 674;ASP A 678","7AE A1000 (-3.7A);None;7AE A1000 ( 4.8A)","0.63A","3v5wA-5td2A:10.0","3mssD-5td2A:41.69"],["3WZE_A_BAXA1201_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",8,"LEU A 593;VAL A 601;ALA A 617;LYS A 619;PHE A 673;GLY A 677;LEU A 714;HIS A 721","7AE A1000 ( 3.9A);7AE A1000 ( 4.9A);7AE A1000 (-3.3A);7AE A1000 (-3.1A);7AE A1000 (-4.1A);7AE A1000 ( 3.7A);None;None","0.67A","3wzeA-5td2A:29.4","3v5wA-5td2A:17.71"],["3ZBF_A_VGHA3000_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",8,"LEU A 593;ALA A 617;LEU A 671;MET A 674;GLY A 677;ASP A 678;THR A 681;ASP A 741","7AE A1000 ( 3.9A);7AE A1000 (-3.3A);7AE A1000 (-3.7A);None;7AE A1000 ( 3.7A);7AE A1000 ( 4.8A);None;7AE A1000 (-4.4A)","0.61A","3zbfA-5td2A:30.4","3wzeA-5td2A:39.68"],["4ANQ_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",8,"LEU A 593;VAL A 601;ALA A 617;LEU A 671;MET A 674;GLY A 677;ALA A 740;ASP A 741","7AE A1000 ( 3.9A);7AE A1000 ( 4.9A);7AE A1000 (-3.3A);7AE A1000 (-3.7A);None;7AE A1000 ( 3.7A);7AE A1000 ( 3.7A);7AE A1000 (-4.4A)","0.52A","4anqA-5td2A:29.0","3zbfA-5td2A:40.25"],["4ANS_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",7,"LEU A 593;VAL A 601;ALA A 617;MET A 674;GLY A 677;ALA A 740;ASP A 741","7AE A1000 ( 3.9A);7AE A1000 ( 4.9A);7AE A1000 (-3.3A);None;7AE A1000 ( 3.7A);7AE A1000 ( 3.7A);7AE A1000 (-4.4A)","0.57A","4ansA-5td2A:28.9","4anqA-5td2A:34.27"],["4ASD_A_BAXA1500_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",8,"LEU A 593;VAL A 601;ALA A 617;LYS A 619;PHE A 673;GLY A 677;LEU A 714;HIS A 721","7AE A1000 ( 3.9A);7AE A1000 ( 4.9A);7AE A1000 (-3.3A);7AE A1000 (-3.1A);7AE A1000 (-4.1A);7AE A1000 ( 3.7A);None;None","0.72A","4asdA-5td2A:29.0","4ansA-5td2A:34.45"],["4IAA_A_RTZA401_1","SERINE\/THREONINE-PROTEIN KINASE PIM-1","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",6,"VAL A 601;ALA A 617;LYS A 619;LEU A 671;ASP A 678;ASP A 741","7AE A1000 ( 4.9A);7AE A1000 (-3.3A);7AE A1000 (-3.1A);7AE A1000 (-3.7A);7AE A1000 ( 4.8A);7AE A1000 (-4.4A)","0.75A","4iaaA-5td2A:20.8","4asdA-5td2A:36.52"],["4TWP_A_AXIA601_1","TYROSINE-PROTEIN KINASE ABL1","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",8,"VAL A 601;ALA A 617;PHE A 673;MET A 674;GLY A 677;ASN A 728;ALA A 740;ASP A 741","7AE A1000 ( 4.9A);7AE A1000 (-3.3A);7AE A1000 (-4.1A);None;7AE A1000 ( 3.7A);7AE A1000 (-4.7A);7AE A1000 ( 3.7A);7AE A1000 (-4.4A)","0.60A","4twpA-5td2A:29.9","4iaaA-5td2A:25.55"],["4TWP_B_AXIB601_1","TYROSINE-PROTEIN KINASE ABL1","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",9,"LEU A 593;VAL A 601;ALA A 617;PHE A 673;MET A 674;GLY A 677;ASN A 728;ALA A 740;ASP A 741","7AE A1000 ( 3.9A);7AE A1000 ( 4.9A);7AE A1000 (-3.3A);7AE A1000 (-4.1A);None;7AE A1000 ( 3.7A);7AE A1000 (-4.7A);7AE A1000 ( 3.7A);7AE A1000 (-4.4A)","0.63A","4twpB-5td2A:16.9","4twpA-5td2A:44.56"],["4U5J_A_RXTA601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",8,"LEU A 593;VAL A 601;ALA A 617;MET A 674;GLY A 677;ASN A 728;ALA A 740;ASP A 741","7AE A1000 ( 3.9A);7AE A1000 ( 4.9A);7AE A1000 (-3.3A);None;7AE A1000 ( 3.7A);7AE A1000 (-4.7A);7AE A1000 ( 3.7A);7AE A1000 (-4.4A)","0.54A","4u5jA-5td2A:21.7","4twpB-5td2A:44.56"],["4U5J_B_RXTB601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",6,"LEU A 593;VAL A 601;ALA A 617;MET A 674;GLY A 677;ASP A 741","7AE A1000 ( 3.9A);7AE A1000 ( 4.9A);7AE A1000 (-3.3A);None;7AE A1000 ( 3.7A);7AE A1000 (-4.4A)","0.71A","4u5jB-5td2A:21.5","4u5jA-5td2A:38.13"],["4V01_A_0LIA1776_1","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",5,"ALA A 617;MET A 641;LEU A 714;HIS A 721;ALA A 740","7AE A1000 (-3.3A);None;None;None;7AE A1000 ( 3.7A)","0.71A","4v01A-5td2A:29.6","4u5jB-5td2A:38.13"],["4V01_B_0LIB1770_1","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",5,"ALA A 617;MET A 641;LEU A 714;HIS A 721;ALA A 740","7AE A1000 (-3.3A);None;None;None;7AE A1000 ( 3.7A)","0.59A","4v01B-5td2A:29.9","4v01A-5td2A:41.42"],["4WA9_A_AXIA9000_1","TYROSINE-PROTEIN KINASE ABL1","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",6,"LEU A 593;ALA A 617;MET A 674;GLY A 677;ASN A 728;ALA A 740","7AE A1000 ( 3.9A);7AE A1000 (-3.3A);None;7AE A1000 ( 3.7A);7AE A1000 (-4.7A);7AE A1000 ( 3.7A)","0.71A","4wa9A-5td2A:27.8","4v01B-5td2A:41.42"],["4WA9_B_AXIB9000_1","TYROSINE-PROTEIN KINASE ABL1","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",7,"VAL A 601;ALA A 617;PHE A 673;MET A 674;GLY A 677;ASN A 728;ALA A 740","7AE A1000 ( 4.9A);7AE A1000 (-3.3A);7AE A1000 (-4.1A);None;7AE A1000 ( 3.7A);7AE A1000 (-4.7A);7AE A1000 ( 3.7A)","0.61A","4wa9B-5td2A:29.0","4wa9A-5td2A:42.38"],["5AAA_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",7,"LEU A 593;VAL A 601;ALA A 617;LEU A 671;MET A 674;GLY A 677;ASP A 741","7AE A1000 ( 3.9A);7AE A1000 ( 4.9A);7AE A1000 (-3.3A);7AE A1000 (-3.7A);None;7AE A1000 ( 3.7A);7AE A1000 (-4.4A)","0.50A","5aaaA-5td2A:12.8","4wa9B-5td2A:42.38"],["5AAB_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",7,"LEU A 593;VAL A 601;ALA A 617;LEU A 671;MET A 674;GLY A 677;ASP A 741","7AE A1000 ( 3.9A);7AE A1000 ( 4.9A);7AE A1000 (-3.3A);7AE A1000 (-3.7A);None;7AE A1000 ( 3.7A);7AE A1000 (-4.4A)","0.51A","5aabA-5td2A:21.1","5aaaA-5td2A:38.05"],["5AAC_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",7,"LEU A 593;VAL A 601;ALA A 617;LEU A 671;MET A 674;GLY A 677;ASP A 741","7AE A1000 ( 3.9A);7AE A1000 ( 4.9A);7AE A1000 (-3.3A);7AE A1000 (-3.7A);None;7AE A1000 ( 3.7A);7AE A1000 (-4.4A)","0.38A","5aacA-5td2A:21.2","5aabA-5td2A:38.05"],["5AJQ_A_DB8A800_1","SERINE\/THREONINE-PROTEIN KINASE 10","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",7,"LEU A 593;GLY A 594;ALA A 617;PHE A 673;GLY A 677;ALA A 740;ASP A 741","7AE A1000 ( 3.9A);7AE A1000 ( 4.2A);7AE A1000 (-3.3A);7AE A1000 (-4.1A);7AE A1000 ( 3.7A);7AE A1000 ( 3.7A);7AE A1000 (-4.4A)","1.04A","5ajqA-5td2A:17.8","5aacA-5td2A:37.74"],["5XV7_A_EMHA705_1","SERINE-ARGININE (SR) PROTEIN KINASE 1","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",5,"LEU A 593;GLY A 594;VAL A 601;ALA A 617;ALA A 740","7AE A1000 ( 3.9A);7AE A1000 ( 4.2A);7AE A1000 ( 4.9A);7AE A1000 (-3.3A);7AE A1000 ( 3.7A)","0.28A","5xv7A-5td2A:19.7","5ajqA-5td2A:25.63"],["6HD4_B_STIB602_1","TYROSINE-PROTEIN KINASE ABL1","5td2","TYROSINE-PROTEIN KINASE MER","Homo sapiens",4,"LEU A 593;PHE A 673;MET A 674;GLY A 677","7AE A1000 ( 3.9A);7AE A1000 (-4.1A);None;7AE A1000 ( 3.7A)","0.60A","6hd4B-5td2A:28.4","5xv7A-5td2A:14.08"]]